Sandbox:AyeshaFJ: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{| class="wikitable" | |||
|+ | |||
! colspan="2" |Acne vulgaris | |||
|- | |||
|Clinical features | |||
| | |||
* '''Comedonal acne''': Closed or open comedones on forehead, nose and chin. | |||
* '''Inflammatory acne:''' Small, erythematous papules and pustules. | |||
* '''Nodular acne:''' Large painful nodules; sinus tracts and scarring. | |||
|- | |||
|Pathogenesis | |||
| | |||
* Hyperkeratinization and obstruction of the pilosebacous follicles. | |||
* Sebaceous gland enlargement and increased sebum production. | |||
* Metabolism of sebaceous lipids by Cutibacterium acnes and release of inflammatory fatty acid. | |||
* Follicular inflammation and rupture, | |||
|- | |||
|Risk factors | |||
|i) Increased circulating androgen (e.g. PCOS, puberty) | |||
ii) Mechanical trauma/friction (excessive scrubbing, tight clothing) | |||
iii) Comedogenic oil based skin and hair products. | |||
iv) Excessive heat. | |||
v) Obesity | |||
|} | |||
Revision as of 09:38, 15 May 2020
Acne vulgaris | |
---|---|
Clinical features |
|
Pathogenesis |
|
Risk factors | i) Increased circulating androgen (e.g. PCOS, puberty)
ii) Mechanical trauma/friction (excessive scrubbing, tight clothing) iii) Comedogenic oil based skin and hair products. iv) Excessive heat. v) Obesity |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Criteria for the diagnosis of SLE | |
---|---|
Clinical features | Characteristics |
1)Malar rash | Fixed erythema, flat or raised, sparing the nasolabial folds |
2)Discoid rash | Erythematous raised patches with adherent keratotic scarring and follicular plugging. |
3)Photosensitivity | Rash due to unusual reaction to sunlight. |
4)Oral ulcer | Oral or nasopharyngeal ulcers, which may be painless. |
5)Arthritis | Non-erosive arthritis, involving >2 peripheral joints. |
6)Serositis | Pleuritis or pericarditis |
7)Renal disorder | Persistent proteinura ( >0.5g/24hrs) or cellular casts (red cell, granular or tubular). |
8)Neurological disorder | Seizure or psychosis, in the absence of provoking drugs or metabolic derangement. |
9)Hematological disorder | Haemolytic anemia or leucopenia (<4 x109) or lymphopenia (<1x109) or thrombocytopenia (<100x109) in the absence of offending drugs. |
10)Immunological | Abnormal titre of Anti-DNA antibodies or presence of Sm antigen or positive antiphospholipid antibodies. |
11)Anti-nuclear Antibody (ANA) | Abnormal ANA titre measured by immunofluorescence |
Diagnosis of SLE is made in an adult if 4 out of 11 features are present either serially or simultaneously. |
- Erythematous raised patches with adherent keratotic scarring and follicular plugging.
Congenital anomalies of the urinary system | |||||||||||||||||||||||||||||||||||
Kidneys | Renal pelvis | Ureter | |||||||||||||||||||||||||||||||||
Renal agenesis | Duplication of renal pelvis | Duplication of ureter | |||||||||||||||||||||||||||||||||
Renal ectopia | Congenital megaureter | ||||||||||||||||||||||||||||||||||
Horseshoe kidney | Post-caval ureter | ||||||||||||||||||||||||||||||||||
Unilateral fusion | Ureterocele | ||||||||||||||||||||||||||||||||||
Congenital cystic kidney | |||||||||||||||||||||||||||||||||||
Infantile polycystic kidney | |||||||||||||||||||||||||||||||||||
Unlilateral Multicystic Kidney | |||||||||||||||||||||||||||||||||||
Simple cyst of the kidney | |||||||||||||||||||||||||||||||||||
Aberrant renal vessels | |||||||||||||||||||||||||||||||||||
Mycosis fungoides | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stage IA-IIA | Stage IIA | Stage III | Stage IV | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Expectane policy • Topical steroides [IV-A] • nb-UVB[III,A] • PUVA [III-A] • Topical mechlorethamine [II,B] • Local RT [IV,A] | • Skin direct therapy(SDT) + local radiotherapy • ST[III+A] • (SDT+) retiods[III,B] • (SDT+) IFN a {III,B] • TSEBT [III,A] | • (SDT+) retinoides • (SDT+) IFNa • ECPI INFa +/- rtinoides • Low dose MTX • [IV-B] | • Gemcitabine • Liposomal doxorubicin • Brentuximab vedotin[II,B] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• (SDT+) retinoides [III,B] • (SDT+) IFNa [III,B] • Retinoides +IFN a [II,B] • TSEBT [IV,A] | • Gemcitabin [IV,B] • Liposomal doxorubicin [IV,B] • Brentuximabvedotin [II,B] • Combinatio Cht [Iv,B] • AlloSCT[V,C] | TSEBT[LV,B] | • Combination Cht [IV,B] • AlloSCT [V,C] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||